4 results
The primary objectives of this study are: * To characterize the effects of 150 mg and 450 mg of AT1001 administered 2 hours before administration of agalsidase on the safety and plasma pharmacokinetics of agalsidase in subjects with Fabry Disease*…
The objectives of this open-label study are to evaluate the efficacy (GL-3 clearance), pharmacokinetics (PK), and safety parameters (including immunogenicity) for 2 alternative dose regimens of Fabrazyme (0.5 mg/kg every 2 weeks [q2w] and 1.0 mg/kg…
To investigate:- Whether a harm reduction strategy with education and counseling is effective in reducing the use of AAS by amateur athletes. - The harm reduction potential of an additional online consultation with a well-known fitness expert. -…
The primary objective of this trial is to test if these favorable results with the DLBP can be upheld in a multicenter randomized controlled trial with patients up to 65 years with a displaced FNF. We hypothesize that the DLBP is superior compared…